Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 (NCT04613596)
A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation
🩺 Plain-English Summary (8th-Grade Level)
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutation and PD-L1 TPS \>=50% and who are candidates for first line treatment.
Who can join: Review the eligibility criteria below.
Location: Local Institution - 007-556-A — Goodyear, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (770 Sites)
Showing the first 25 of 770 sites.
- Local Institution - 007-556-A — Goodyear, Arizona
- USOR - Arizona Oncology - Prescott Valley — Prescott Valley, Arizona
- Local Institution - 007-568-A — Safford, Arizona
- Local Institution - 007-568-B — Safford, Arizona
- Local Institution - 007-568-C — Safford, Arizona
- Local Institution - 007-568-D — Safford, Arizona
- Local Institution - 007-568-E — Safford, Arizona
- Arizona Clinical Research Center — Tucson, Arizona
- Highlands Oncology Group - Springdale — Springdale, Arkansas
- Providence - Saint Joseph Home Health - Anaheim — Anaheim, California
- The Oncology Institute of Hope and Innovation - Corporate Office — Cerritos, California
- Local Institution - 007-777 — Fountain Valley, California
- Local Institution - 007-778 — Laguna Hills, California
- Local Institution - 007-898-B — Long Beach, California
- MemorialCare - Long Beach Medical Center — Long Beach, California
- TRIO - Cancer & Blood Specialty Clinic - Los Alamitos — Los Alamitos, California
- Local Institution - 007-579 — Los Angeles, California
- Local Institution - Unk045 — Rancho Mirage, California
- San Francisco Veterans Affairs Medical Center — San Francisco, California
- UCSF Helen Diller Family Comprehensive Cancer Center — San Francisco, California
- Local Institution - 007-898-C — Santa Ana, California
- Providence Medical Group - Santa Rosa — Santa Rosa, California
- Stockton Hematology Oncology Medical Group (SHOMG) - Stockton (Suite B) — Stockton, California
- Local Institution - 007-898-A — Whittier, California
- Local Institution - 007-872-H — Aurora, Colorado
📞 Contact the Study Coordinator
Phone: (855) 907-3286
Email: Clinical.Trials@bms.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Non-Small Cell Lung Cancer
- A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) — Los Angeles, California
- Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients — Tarrytown, New York
- A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) — Tucson, Arizona
- The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer — New Haven, Connecticut
- Study With Various Immunotherapy Treatments in Participants With Lung Cancer — Birmingham, Alabama
- Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — Bullhead City, Arizona
Explore by condition: All Advanced Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.